Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 15 November 2005
Vol. 2005, Issue 310, p. tw409
[DOI: 10.1126/stke.3102005tw409]


PHARMACOLOGY Targeting TNF-α Interactions

The proinflammatory cytokine, tumor necrosis factor-α (TNF-α ), plays a role in diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. TNF-α forms a homotrimer that binds to the TNF receptor to activate inflammatory responses. Although antibodies against TNF-α or soluble versions of the receptor are therapeutically effective, rationally designed small-molecule drugs that target protein-protein interactions would be useful. He et al. report on a small-molecule inhibitor that functions by dissociating the TNF-α trimer. The inhibitor binds to the intact biologically active trimer, accelerates subunit dissociation, and forms a complex with a dimer of TNF-α subunits.

M. M. He, A. S. Smith, J. D. Oslob, W. M. Flanagan, A. C. Braisted, A. Whitty, M. T. Cancilla, J. Wang, A. A. Lugovskoy, J. C. Yoburn, A. D. Fung, G. Farrington, J. K. Eldredge, E. S. Day, L. A. Cruz, T. G. Cachero, S. K. Miller, J. E. Friedman, I. C. Choong, B. C. Cunningham, Small-molecule inhibition of TNF-α. Science 310, 1022-1025 (2005). [Abstract] [Full Text]

Citation: Targeting TNF-α Interactions. Sci. STKE 2005, tw409 (2005).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882